Nasopharyngeal carcinoma: treatments and outcomes in the 20th century.
about
Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapyOutpatient weekly 24-hour infusional adjuvant chemotherapy of cisplatin, 5-fluorouracil, and leucovorin for high-risk nasopharyngeal carcinoma.Treatment of locally advanced head and neck cancer: historical and critical review.Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence populationA phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma.Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.Trends in the survival of patients with nasopharyngeal carcinoma between 1976 and 2005 in Sihui, China: a population-based study.Nutlin-3, A P53-Mdm2 Antagonist For Nasopharyngeal Carcinoma Treatment.Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.CT-guided 125I brachytherapy for locally recurrent nasopharyngeal carcinoma.Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals.Spontaneous T cell responses to Epstein-Barr virus-encoded BARF1 protein and derived peptides in patients with nasopharyngeal carcinoma: bases for improved immunotherapy.Association between the p73 G4C14-to-A4T14 polymorphism and risk of nasopharyngeal carcinoma: a case-control and family-based study.Prognostic significance of expression of VEGF and Cox-2 in nasopharyngeal carcinoma and its association with expression of C-erbB2 and EGFR.
P2860
Q33305203-DB8E7660-CF44-46DA-8D22-17242CA1A5A4Q33348288-F2F72FF1-80A2-4F6E-A95F-75FE3D698EB9Q34157174-14F2ABE9-2A67-4828-8E1A-7D09A50D80D8Q34242449-5D77B2D4-0EAA-4762-A37D-03338A8F9F2BQ34351822-5243310C-0D32-4104-848E-64710CB41968Q35857642-6B37FB23-7236-4901-ABA4-7DE05ED01DE5Q37129671-6B11F63E-A2DC-4258-90EC-2503B8D0460DQ37248002-AC8C3112-DFCC-4C20-A31D-E4AE2EFDB562Q37354125-869501C7-E4E0-4556-B6D8-E1A09F6EC62FQ38656647-EFC8402D-BB09-4FC2-B797-46365CD60492Q39170011-26FA8E3D-9B25-4CCC-A4FB-DA806B4A5EADQ41439939-5D9C1BCD-B223-45C3-BD72-2A36EE7935C6Q45029775-58616050-A633-4246-A96F-A3F4D6D0BD7CQ45394514-63E5F505-4512-4EFD-80C5-626BF7BB38FEQ53063986-DF0141E0-4865-4B34-9193-68B1A4E257ECQ54637355-D0395ED1-64DE-4B15-80A3-41C08284BE52
P2860
Nasopharyngeal carcinoma: treatments and outcomes in the 20th century.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Nasopharyngeal carcinoma: treatments and outcomes in the 20th century.
@ast
Nasopharyngeal carcinoma: treatments and outcomes in the 20th century.
@en
Nasopharyngeal carcinoma: treatments and outcomes in the 20th century.
@nl
type
label
Nasopharyngeal carcinoma: treatments and outcomes in the 20th century.
@ast
Nasopharyngeal carcinoma: treatments and outcomes in the 20th century.
@en
Nasopharyngeal carcinoma: treatments and outcomes in the 20th century.
@nl
prefLabel
Nasopharyngeal carcinoma: treatments and outcomes in the 20th century.
@ast
Nasopharyngeal carcinoma: treatments and outcomes in the 20th century.
@en
Nasopharyngeal carcinoma: treatments and outcomes in the 20th century.
@nl
P2860
P1476
Nasopharyngeal carcinoma: treatments and outcomes in the 20th century.
@en
P2860
P304
P356
10.1259/BJR.75.892.750307
P407
P577
2002-04-01T00:00:00Z